Atlantic Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Atlantic Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$818	Hold	15	–	–	﹤0.01%	247
2026 Q1	$714	Hold	15	–	–	﹤0.01%	256
2025 Q4	$787	Hold	15	–	–	﹤0.01%	276
2025 Q3	$972	Hold	15	–	–	﹤0.01%	229
2025 Q2	$730	Hold	15	–	–	﹤0.01%	229
2025 Q1	$510	Buy	+15	New	+$636	﹤0.01%	204
2024 Q4	–	Sell	-15	Closed	-$704	–	198
2024 Q3	$704	Hold	15	–	–	﹤0.01%	179
2024 Q2	$810	Hold	15	–	–	﹤0.01%	99
2024 Q1	$1.02K	Buy	+15	New	+$1.07K	﹤0.01%	104

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atlantic Private Wealth's CRSP Position: Q2 2026 in Review

Atlantic Private Wealth held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 15 shares worth $818. The position accounts for ﹤0.01% of the portfolio, ranked #247.

Atlantic Private Wealth first reported a position in CRSP in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.02K in Q1 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Atlantic Private Wealth held 15 shares of CRISPR Therapeutics worth $818 as of Q2 2026.
Atlantic Private Wealth left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Atlantic Private Wealth's portfolio in Q2 2026, its #247 holding.
Atlantic Private Wealth first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 9 quarters since.
Atlantic Private Wealth's CRISPR Therapeutics position peaked at $1.02K in Q1 2024.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Atlantic Private Wealth's 13F filing for Q2 2026, filed 11 Aug 2026.